119 related articles for article (PubMed ID: 20009467)
1. [A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Kiyoto S; Hara F; Osumi S; Takabatake D; Takashima S; Aogi K; Takashima S
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2623-5. PubMed ID: 20009467
[TBL] [Abstract][Full Text] [Related]
2. [A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
Shibaki T; Morimoto N
Gan To Kagaku Ryoho; 2010 Mar; 37(3):499-501. PubMed ID: 20332691
[TBL] [Abstract][Full Text] [Related]
3. [Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
Hoshino K; Nakamura M; Ikeda H; Koyama T; Morishita Y
Gan To Kagaku Ryoho; 1999 Jun; 26(7):983-7. PubMed ID: 10396328
[TBL] [Abstract][Full Text] [Related]
4. [A case of an elderly breast cancer patient achieving partial response with toremifene without efficacy of letrozole as a preoperative primary endocrine therapy].
Arai T; Ooshiro C; Kamigaki S; Miwa H; Yoneda G; Harada H; Furukawa H
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2627-9. PubMed ID: 22189230
[TBL] [Abstract][Full Text] [Related]
5. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
[TBL] [Abstract][Full Text] [Related]
6. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
7. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
9. [A case of liver metastasis of breast cancer responding to letrozole].
Hata K; Hirai I; Tanaka T; Tanino H
Gan To Kagaku Ryoho; 2012 Feb; 39(2):257-60. PubMed ID: 22333638
[TBL] [Abstract][Full Text] [Related]
10. [A case of recurrent breast cancer with solitary adrenal metastasis treated with surgery and endocrine therapy].
Yoshitomi S; Tsuji H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2074-6. PubMed ID: 23267981
[TBL] [Abstract][Full Text] [Related]
11. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
12. [Recurrence of skin and lymph nodes from asynchronous breast cancer successfully treated with paclitaxel and toremifene therapy--a case report].
Sakurai K; Enomoto K; Tani M; Kitajima A; Amano S; Shiono M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2222-4. PubMed ID: 19106577
[TBL] [Abstract][Full Text] [Related]
13. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
14. The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Pennery E
Eur J Oncol Nurs; 2008 Jul; 12(3):233-43. PubMed ID: 18372213
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
17. [A case of long-term survival of liver metastasis of breast cancer successfully treated with chemotherapy and endocrine therapy].
Shiba E; Koyama H; Sasaki Y; Iwanaga T; Terasawa T; Wada A
Gan No Rinsho; 1985 Sep; 31(11):1439-44. PubMed ID: 3934423
[TBL] [Abstract][Full Text] [Related]
18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
19. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
20. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
